ZCCHC10

ZCCHC10 is a tumor suppressor that converges on p53 stabilization and telomerase repression to restrain cancer cell proliferation and invasion (PMID:31138778, PMID:31404068). It directly binds p53 and competitively disrupts the p53–MDM2 interaction, blocking MDM2-mediated ubiquitination and degradation and thereby stabilizing p53 protein; this activity is strictly dependent on wild-type p53, as ZCCHC10 has no effect in p53-null or p53-mutant lung cancer cells (PMID:31138778). Independently, ZCCHC10 interacts with the homeodomain transcription factor PITX1 through PITX1's homeodomain, and the resulting complex cooperatively represses transcription from the hTERT promoter (PMID:31404068). ZCCHC10 expression is itself subject to negative regulation: miR-410-3p directly targets its 3′UTR to lower ZCCHC10 protein, and loss of ZCCHC10 derepresses NF-κB signaling to drive epithelial–mesenchymal transition, migration, and invasion in colorectal cancer cells (PMID:33517196); in acute myeloid leukemia, the lncRNA SNHG1 silences ZCCHC10 by recruiting DNMT1 and DNMT3B to its promoter CpG island for hypermethylation, and restoring ZCCHC10 raises p53 levels, suppresses proliferation, and sensitizes cells to venetoclax (PMID:37052262). The biochemical activity of the ZCCHC10 protein itself beyond these binding-mediated functions has not been characterized in the available corpus.

1. 2019 High

   Established ZCCHC10 as a direct p53-stabilizing tumor suppressor, defining its first mechanistic role by showing it physically guards p53 from MDM2-driven degradation.

   Evidence Co-IP, overexpression/knockdown in lung cancer lines, pifithrin-α/Nutlin3 epistasis rescue, and xenograft assays

   PMID:31138778

   Open questions at the time

   • Does not map which ZCCHC10 domain or residues mediate p53 binding or MDM2 displacement
   • No structural model of the ZCCHC10–p53 complex
   • Whether ZCCHC10 itself has enzymatic activity is unaddressed
2. 2019 Medium

   Revealed a second, p53-independent output by showing ZCCHC10 partners with PITX1 to transcriptionally repress hTERT, linking it to telomerase control.

   Evidence FLAG pull-down, transcriptional reporter assays, and PITX1 homeodomain deletion mutagenesis in melanoma cells

   PMID:31404068

   Open questions at the time

   • Reciprocal interaction shown in a single lab
   • How ZCCHC10 contributes mechanistically to repression (DNA binding vs. cofactor recruitment) is unresolved
   • Relationship between hTERT repression and the p53 axis is not integrated
3. 2021 Medium

   Identified an upstream silencing mechanism and a downstream invasion phenotype, showing miR-410-3p suppresses ZCCHC10 to unleash NF-κB-driven EMT.

   Evidence Dual-luciferase 3′UTR reporter, miRNA mimic/siRNA, BAY 11-7082 NF-κB inhibitor rescue, and migration/invasion assays in colorectal cancer cells

   PMID:33517196

   Open questions at the time

   • How ZCCHC10 loss mechanistically activates NF-κB is not defined
   • Whether NF-κB regulation depends on the p53 axis is untested
   • Single-lab validation
4. 2023 Medium

   Demonstrated epigenetic silencing of ZCCHC10 in AML and connected its restoration to p53 elevation and drug sensitivity, reinforcing the tumor-suppressor model therapeutically.

   Evidence Promoter methylation/ChIP, SNHG1–DNMT1/DNMT3B RNA-IP, SNHG1 deletion mutants, ZCCHC10 overexpression, and venetoclax sensitization in AML lines and xenografts

   PMID:37052262

   Open questions at the time

   • Does not establish whether the p53 increase is direct or secondary to proliferation arrest
   • Single-lab study
   • Generality of SNHG1-driven silencing across other cancers unknown

• The intrinsic biochemical activity of the ZCCHC10 protein and how its multiple binding-mediated roles (p53 stabilization, PITX1/hTERT repression, NF-κB restraint) are coordinated remain unresolved.
• No defined catalytic or nucleic-acid-binding activity for ZCCHC10
• No structural characterization of any ZCCHC10 complex
• Whether the p53, telomerase, and NF-κB functions operate in the same cells or are tissue-specific is unknown